Novel Agents in Pancreatic Cancer

Video

This video covers the latest research in pancreatic cancer, including the possible role of PARP inhibitors, immunotherapy, and the novel drug PEGPH20.

In this video, Philip A. Philip, MD, PhD, of the Barbara Ann Karmanos Cancer Institute in Detroit, discusses the latest research developments and progress in the treatment of pancreatic cancer.

Philip touches on newer chemotherapy regimens such as FOLFIRINOX and gemcitabine plus nab-paclitaxel and highlights immunotherapy in this setting and targeted agents such as PARP inhibitors and a novel drug, pegylated recombinant human hyaluronidase (PEGPH20).

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer

Roman Fabbricatore
August 22nd 2025
Article

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.

Low Dose-Averaged LET Exhibits Poor Local Control in Pancreatic Cancer

Roman Fabbricatore
August 20th 2025
Article

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.

Phase 1 data may support continued research of amphiphile lymph node-targeted immunotherapy in solid tumors.

Novel Vaccine Shows Early Responses in Pancreatic Cancer and CRC

Russ Conroy
August 18th 2025
Article

Phase 1 data may support continued research of amphiphile lymph node–targeted immunotherapy in solid tumors.